{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02338375",
      "OrgStudyIdInfo": {
        "OrgStudyId": "2012-10-078"
      },
      "Organization": {
        "OrgFullName": "Samsung Medical Center",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product",
      "OfficialTitle": "Clinical Trial of the Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product With Microfracture for Osteochondral Lesion of Talus Patients",
      "Acronym": "Cartistem"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2015",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Enrolling by invitation",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 2012"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "August 2015",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2015",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "July 31, 2013",
      "StudyFirstSubmitQCDate": "January 11, 2015",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 14, 2015",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "January 11, 2015",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 14, 2015",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "ChulWon Ha",
        "ResponsiblePartyInvestigatorTitle": "MD",
        "ResponsiblePartyInvestigatorAffiliation": "Samsung Medical Center"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Samsung Medical Center",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate the safety and efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) on currently standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus.",
      "DetailedDescription": "same as above"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Osteochondral Lesion of Talus"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Early Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "28",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Cartistem",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "For control group patients currently standard treatment of arthroscopic curettage and microfracture is performed, and for study group patients allogenic umbilical cord blood-derived mesenchymal stem cell product(Cartistem®) is added on the lesion after above mentioned procedure.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Cartistem"
              ]
            }
          },
          {
            "ArmGroupLabel": "standard treatment",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Cartistem"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Cartistem",
            "InterventionDescription": "Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Cartistem",
                "standard treatment"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by American Orthopaedic Foot and Ankle Society(AOFAS) HINDFOOT/ANKLE SCALE",
            "PrimaryOutcomeTimeFrame": "Baseline, Week 4, Week 8, Week 12, Week 24, Week 48"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by 100-mm VAS(Visual Analogue Scale)",
            "SecondaryOutcomeTimeFrame": "Baseline, Week 4, Week 8, Week 12, Week 24, Week 48"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem®) by ICRS arthroscopic scale for repair of articular cartilage",
            "OtherOutcomeTimeFrame": "Baseline, Week 4, Week 8, Week 12, Week 24, Week 48"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nNon-responder to conservative treatment for radiographically confirmed (by MRI) osteochondral lesion of talus with ankle pain and/or stiffness and less than 75 of the AOFAS score\nAge between 20 and 70 year-old\nAppropriate function of blood clot PT(INR) < 1.5, APTT <1.5×control\nAppropriate renal function Creatinine ≤ 2.0 ㎎/㎗, proteinuria less than trace with Dipstick urine test\nAppropriate hepatic function Bilirubin ≤ 2.0 ㎎/㎗, AST/ALT ≤ 100 IU/L\nNo evidence of autoimmue disorder As screening test anti-nuclear antibody and/or anti-thyroglobulin antibody, if positive rheumatologist referral needed to confirm diagnosis\nNo surgery or radiotherapy for the same ankle joint within 6 weeks\nFemale patients agreeing with maintenance of contraception during study period\nNo ligament instability greater than grade II (Grade 0 : none, Grade Ⅰ: 0~5㎜, GradeⅡ: 5~10㎜, Grade Ⅲ: >10㎜) with physical exam\nPatients agreeing with participation in this study and signed on informed consent by their own will\n\nExclusion Criteria:\n\nDegenerative ankle arthritis patients\nPatients with autoimmune disease\nPatients with infectious disease needed parenteral antibiotics\nPatients with myocardial infarction, congestive heart failure, other serious heart diseases or uncontrollable hypertion\nPatients with other serious medical illness\nPregnancy or breast feeding patients\nPast history related with psychiatric illness or epilepsy\nAlcoholic abuse\nHeavy smoker\nChronic inflammatory disease including rheumatoid arthritis\nParticipants of other clinical trial within 4 weeks\nPatients treated with immunosuppressing agents such as Cyclosporin A or azathioprine within 6 weeks\nUnstable ankle joint(lesion site) greater than grade II at physical exam (Grade 0 : none, grade Ⅰ: 0~5㎜, GradeⅡ: 5~10㎜, Grade Ⅲ: >10㎜)\nOther inappropriate patients determined by the prinicipal investigator",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "20 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Samsung Medical Center",
            "LocationCity": "Gangnam-Gu",
            "LocationState": "Seoul",
            "LocationZip": "135-710",
            "LocationCountry": "Korea, Republic of"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "T63",
            "InterventionBrowseLeafName": "Astragalus",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "HB",
            "InterventionBrowseBranchName": "Herbal and Botanical"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}